Search
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigationalNemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Synonyms: )-IGHJ5*01) [8.8.14] (1-121) -Homo sapiens IGHG2*0, Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimerClorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitClorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. … In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acidButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicit[L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence. … Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.
Mixtures: Fiorinal-C 1/4, Fiorinal-C 1/2Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersRiltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigationalThe Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]
Mixtures: Comirnaty Original/omicron Ba.1Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalPoractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. … Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.
Products: CUROSURF ® 3.0 ML, CUROSURF 240 MG/3 ML INTRATRAKEAL SUSPANSIYON IÇEREN FLAKON, 1 ADETSagopilone
go.drugbank.com/drugs/DB12391Investigationalmultidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo. … It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer.
Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-RingDarvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawnPerianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms. … [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736ApprovedAllogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the … Birch bark extract is rich in triterpenoids with beneficial biological and pharmacological activities.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 2-Ring